FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4238609664> ?p ?o ?g. }

• W4238609664 abstract "Background Respiratory disease is the major cause of mortality and morbidity in cystic fibrosis (CF). Life expectancy of people with CF has increased dramatically in the last 40 years. One of the major reasons for this increase is the mounting use of antibiotics to treat chest exacerbations caused by bacterial infections. The optimal duration of intravenous antibiotic therapy is not clearly defined. Individuals usually receive intravenous antibiotics for 14 days, but treatment may range from 10 to 21 days. A shorter duration of antibiotic treatment risks inadequate clearance of infection which could lead to further lung damage. Prolonged courses of intravenous antibiotics are expensive and inconvenient and the incidence of allergic reactions to antibiotics also increases with prolonged courses. The use of aminoglycosides requires frequent monitoring to avoid some of their side effects. However, some organisms which infect people with CF are known to be multi‐resistant to antibiotics, and may require a longer course of treatment. Objectives To assess the optimal duration of intravenous antibiotic therapy for treating chest exacerbations in people with cystic fibrosis. Search methods We searched the Cochrane Cystic Fibrosis and Genetic Disorders Group Trials Register which comprises references identified from comprehensive electronic database searches, handsearches of relevant journals, abstract books and conference proceedings. Most recent search of the Group's Cystic Fibrosis Trials Register: 15 November 2012. Selection criteria Randomised and quasi‐randomised controlled trials comparing different durations of intravenous antibiotic courses for acute respiratory exacerbations in people with CF, either with the same drugs at the same dosage, the same drugs at a different dosage or frequency or different antibiotics altogether, including studies with additional therapeutic agents. Data collection and analysis No eligible trials were identified. Main results No eligible trials were identified. Authors' conclusions There are no clear guidelines on the optimum duration of intravenous antibiotic treatment. Duration of treatment is currently based on unit policies and response to treatment. Shorter duration of treatment should improve quality of life and compliance; result in a reduced incidence of drug reactions; and be less costly. However, this may not be sufficient to clear a chest infection and may result in an early recurrence of an exacerbation. This systematic review identifies the need for a multicentre, randomised controlled trial comparing different durations of intravenous antibiotic treatment as it has important clinical and financial implications." @default.
• W4238609664 created "2022-05-12" @default.
• W4238609664 creator A5028425686 @default.
• W4238609664 creator A5038748205 @default.
• W4238609664 date "2013-05-31" @default.
• W4238609664 modified "2023-10-16" @default.
• W4238609664 title "Duration of intravenous antibiotic therapy in people with cystic fibrosis" @default.
• W4238609664 cites W1969113368 @default.
• W4238609664 cites W1971558827 @default.
• W4238609664 cites W1971671577 @default.
• W4238609664 cites W1974826069 @default.
• W4238609664 cites W1975806439 @default.
• W4238609664 cites W1975959231 @default.
• W4238609664 cites W1980277180 @default.
• W4238609664 cites W1982069984 @default.
• W4238609664 cites W1983262214 @default.
• W4238609664 cites W1983782536 @default.
• W4238609664 cites W1988667552 @default.
• W4238609664 cites W1996565956 @default.
• W4238609664 cites W2005567520 @default.
• W4238609664 cites W2008210155 @default.
• W4238609664 cites W2009467539 @default.
• W4238609664 cites W2015936552 @default.
• W4238609664 cites W2028274288 @default.
• W4238609664 cites W2028566024 @default.
• W4238609664 cites W2029523760 @default.
• W4238609664 cites W2036276557 @default.
• W4238609664 cites W2038044678 @default.
• W4238609664 cites W2041092399 @default.
• W4238609664 cites W2041756676 @default.
• W4238609664 cites W2045196836 @default.
• W4238609664 cites W2055857822 @default.
• W4238609664 cites W2056538792 @default.
• W4238609664 cites W2056937736 @default.
• W4238609664 cites W2060894544 @default.
• W4238609664 cites W2063508460 @default.
• W4238609664 cites W2072542505 @default.
• W4238609664 cites W2073009316 @default.
• W4238609664 cites W2075282927 @default.
• W4238609664 cites W2088123031 @default.
• W4238609664 cites W2088339823 @default.
• W4238609664 cites W2092206158 @default.
• W4238609664 cites W2092976329 @default.
• W4238609664 cites W2098645786 @default.
• W4238609664 cites W2099684220 @default.
• W4238609664 cites W2101273248 @default.
• W4238609664 cites W2102144745 @default.
• W4238609664 cites W2102677849 @default.
• W4238609664 cites W2103923109 @default.
• W4238609664 cites W2117572142 @default.
• W4238609664 cites W2117621673 @default.
• W4238609664 cites W2117634416 @default.
• W4238609664 cites W2125435699 @default.
• W4238609664 cites W2130235475 @default.
• W4238609664 cites W2142443730 @default.
• W4238609664 cites W2152207716 @default.
• W4238609664 cites W2154385375 @default.
• W4238609664 cites W2155069031 @default.
• W4238609664 cites W2155893984 @default.
• W4238609664 cites W2163773920 @default.
• W4238609664 cites W2166716399 @default.
• W4238609664 cites W2172131043 @default.
• W4238609664 cites W3144760769 @default.
• W4238609664 cites W4252973849 @default.
• W4238609664 cites W4255417176 @default.
• W4238609664 doi "https://doi.org/10.1002/14651858.cd006682.pub4" @default.
• W4238609664 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23728662" @default.
• W4238609664 hasPublicationYear "2013" @default.
• W4238609664 type Work @default.
• W4238609664 citedByCount "13" @default.
• W4238609664 countsByYear W42386096642013 @default.
• W4238609664 countsByYear W42386096642014 @default.
• W4238609664 countsByYear W42386096642015 @default.
• W4238609664 countsByYear W42386096642016 @default.
• W4238609664 countsByYear W42386096642017 @default.
• W4238609664 countsByYear W42386096642018 @default.
• W4238609664 countsByYear W42386096642019 @default.
• W4238609664 countsByYear W42386096642021 @default.
• W4238609664 crossrefType "reference-entry" @default.
• W4238609664 hasAuthorship W4238609664A5028425686 @default.
• W4238609664 hasAuthorship W4238609664A5038748205 @default.
• W4238609664 hasBestOaLocation W42386096642 @default.
• W4238609664 hasConcept C126322002 @default.
• W4238609664 hasConcept C177713679 @default.
• W4238609664 hasConcept C187212893 @default.
• W4238609664 hasConcept C2776938444 @default.
• W4238609664 hasConcept C3020230634 @default.
• W4238609664 hasConcept C501593827 @default.
• W4238609664 hasConcept C71924100 @default.
• W4238609664 hasConcept C86803240 @default.
• W4238609664 hasConcept C89423630 @default.
• W4238609664 hasConceptScore W4238609664C126322002 @default.
• W4238609664 hasConceptScore W4238609664C177713679 @default.
• W4238609664 hasConceptScore W4238609664C187212893 @default.
• W4238609664 hasConceptScore W4238609664C2776938444 @default.
• W4238609664 hasConceptScore W4238609664C3020230634 @default.
• W4238609664 hasConceptScore W4238609664C501593827 @default.
• W4238609664 hasConceptScore W4238609664C71924100 @default.
• W4238609664 hasConceptScore W4238609664C86803240 @default.
• W4238609664 hasConceptScore W4238609664C89423630 @default.

• next